Exemestane in postmenopausal women with early or advanced breast cancer: a review

Bibliography

• Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metabol 1973;36:207-14
   PubMed Web of Science ®Google Scholar
• Schwarzel W, Kruggel WG, Brodie HJ. Studies on the mechanism of estrogen byosynthesis. VIII. The development of inhibitors of the enzyme system in the human palcenta. Endocrinology 1973;92:866-80
   PubMed Web of Science ®Google Scholar
• Griffiths CT, Hall TC, Saba Z, Preliminary trial of aminoglutethimide in breast cancer. Cancer 1973;32:31-7
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol 1996;23:494-505
   PubMedGoogle Scholar
• Santen RJ, Santner S, Davis B, Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978;47:1257-65
   PubMed Web of Science ®Google Scholar
• Santen RJ, Brodie H, Simpson ER, History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev 2009;30:343-75
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JA, Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group. J Clin Oncol 2001;19:2596-606
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Bajetta E, Dirix LY, Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial – the Exemestane Study Group. J Clin Oncol 2000;18:1399-411
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thurlimann B, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-reponsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92
   PubMed Web of Science ®Google Scholar
• Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Guglielmini P, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-47
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, Survival and safety of exemestane versus tamoxifen after 2 – 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Jeong J-H, Wickerham DL, Benefit from exemestane as extended adjuvant therapy following five years of adjuvant tamoxifen: intent-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. J Clin Oncol 2008;26:1965-71
   PubMed Web of Science ®Google Scholar
• Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31
   PubMed Web of Science ®Google Scholar
• Evans TR, Di Salle E, Ornati G, Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933-9
   PubMed Web of Science ®Google Scholar
• Lonning P, Pfister C, Martoni A, Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 2003;30:23-32
   PubMed Web of Science ®Google Scholar
• Scott LJ, Wiseman LR. Exemestane. Drugs 1999;58:675-80
   PubMedGoogle Scholar
• Lonning PE, Paridaens R, Thurlimann B, Exemestane experience in breast cancer treatment. J Steroid Biochem Mol Biol 1997;61:151-5
   PubMedGoogle Scholar
• Jones S, Vogel C, Arkhipov A, Multicenter phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer: Aromasin Study Group. J Clin Oncol 1999;17:3418-25
   PubMed Web of Science ®Google Scholar
• Chia S, Gradishar W, Mauriac L, Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70
   PubMed Web of Science ®Google Scholar
• Paridaens RJ, Dirix LY, Beex LV, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90
   PubMed Web of Science ®Google Scholar
• Lonning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 2009;45:527-35
   PubMed Web of Science ®Google Scholar
• Bertelli G, Garrone O, Merlano M, Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005;69:471-7
   PubMed Web of Science ®Google Scholar
• Robinson A. A review of the use of exemestane in early breast cancer. Ther Clin Risk Manag 2009;5:91-8
   PubMedGoogle Scholar
• Bliss JM, Kilburn LS, Coleman RE, Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES). Cancer Res 2009;69(24 Suppl): abstract 12
   Google Scholar
• Puglisi F, Minisini AM. Adjuvant endocrine therapy in postmenopausal breast cancer patients: does hormone receptor status influence decision-making? Crit Rev Oncol Haematol 2010. [Epub ahead of print]
   Google Scholar
• Jones SE, Seynaeve C, Hasenburg A, Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. Cancer Res 2009;69(Suppl 2): abstract 15
   Google Scholar
• Rea D, Hasenburg A, Seynaeve C, Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer. Cancer Res 2009;69(Suppl 24): abstract 11
   Google Scholar
• Mlineritsch B, Tausch C, Singer C, Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat 2008;112:203-13
   PubMedGoogle Scholar
• Takei H, Suemasu K, Inoue K, Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat 2008;107:87-94
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Mansutti M, Sacco C, Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. Ann Oncol 2009;20:655-9
   PubMedGoogle Scholar
• Lonning PE, Geisler J, Krag LE, Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-37
   PubMed Web of Science ®Google Scholar
• Mccloskey EV, Hannon RA, Lakner G, Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007;43:2523-31
   PubMed Web of Science ®Google Scholar
• Coleman RE, Banks LM, Girgis SI, Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-27
   PubMed Web of Science ®Google Scholar
• Hadji P, Ziller M, Kieback DG, Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 2009;20:1203-9
   PubMed Web of Science ®Google Scholar
• Goss PE, Qi S, Cheung AM, Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004;10:5717-23
   PubMed Web of Science ®Google Scholar
• Crew KD, Greenlee H, Capodice J, Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877-83
   PubMed Web of Science ®Google Scholar
• Bertelli G, Hall E, Ireland E, Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) – a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol 2010;21:498-505
   PubMed Web of Science ®Google Scholar
• Jones SE, Cantrell J, Vukelja S, Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 2007;25:4765-71
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Bliss J, Porter L, Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006;24:910-17
   PubMed Web of Science ®Google Scholar
• Markopoulos C, Polychronis A, Dafni U, Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol 2009;20:49-5
   PubMed Web of Science ®Google Scholar
• Bertelli G, Paridaens R. Optimal sequence of hormonotherapy in advanced breast cancer. Curr Opin Oncol 2006;18:572-7
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Giobbie-Hurder A, Goldhirsch A, ; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76
   PubMed Web of Science ®Google Scholar
• Briot K, Tubiana-Hulin M, Bastit L, Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 2010;120:127-34
   PubMed Web of Science ®Google Scholar